 Bio-Path Holdings, Inc., BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the Audit Committee of the Companys Board of Directors approved the appointment of Ernst Young LLP EY as the Companys new independent registered public accounting firm, replacing former auditor, BDO USA, LLP BDO. We thank BDO for its fine services over the past several years. 